Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HERV-E TCR Transduced Autologous T Cells in Metastatic Clear Cell Renal Cell Carcinoma
NCT03354390Phase 1Active, not recruiting
- Sponsor
- National Heart, Lung, and Blood Institute
- Start
- Jul 2018
- Primary completion
- Oct 2023
- Modality
- TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of HERV-E T-cell receptor transduced CD8+/CD34+ enriched T cells in clear cell renal cell carcinoma (ccRCC) (4 arms), sponsored by National Heart, Lung, and Blood Institute. Primary endpoint: Number of Adverse Events at Least Possible Attributed to Treatment Regime at 21 days. Started Jul 2018; status: active, not recruiting.
02
Drugs
HERV-E T-cell receptor transduced CD8+/CD34+ enriched T cells
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT03354390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03354390.